Studies have suggested a cross-interaction between the mTOR pathway and estrogen receptor signaling, where estrogen E2 binding to the receptor activates Akt/mTOR, thereby mediating PEComa resistance to mTOR inhibitors. The gene discussed is ESR1; the disease is neoplasm with perivascular epithelioid cell differentiation.